Is schizophrenia a metabolic brain disorder? Membrane phospholipid dysregulation and its therapeutic implications

Psychiatric Clinics of North America

Volumn 26, Issue 1, 2003, Pages 85-102

  Mahadik, Sahebarao P ^a,b   Evans, Denise R ^a,b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; APOLIPOPROTEIN D; ARACHIDONIC ACID; ASCORBIC ACID; BASIC FIBROBLAST GROWTH FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; DOCOSAHEXAENOIC ACID; FREE RADICAL; HALOPERIDOL; ICOSAPENTAENOIC ACID; ICOSAPENTAENOIC ACID ETHYL ESTER; MEMBRANE PHOSPHOLIPID; NERVE GROWTH FACTOR; NEUROLEPTIC AGENT; OLANZAPINE; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PHOSPHOLIPASE; PLACEBO; POLYUNSATURATED FATTY ACID; QUETIAPINE; RISPERIDONE;

ANTIOXIDANT ACTIVITY; ARACHIDONIC ACID METABOLISM; BRAIN DEVELOPMENT; BRAIN DISEASE; BRAIN METABOLISM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DIETARY INTAKE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FAT INTAKE; FATTY ACID METABOLISM; HUMAN; LIPID PEROXIDATION; MENTAL DISEASE; NEUROTRANSMISSION; PHOSPHOLIPID MEMBRANE; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SIGNAL TRANSDUCTION; SYMPTOMATOLOGY;

ANTIPSYCHOTIC AGENTS; BRAIN; BRAIN DISEASES, METABOLIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MEMBRANE LIPIDS; NEURONS; PHOSPHOLIPIDS; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 0037349417     PISSN: 0193953X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0193-953X(02)00033-3     Document Type: Review

References (82)

1. Kraepelin E. Dementia praecox and paraphrenia. Edinburgh: Livingstone; 1919.
2. Waddington JL, Buckley PF (eds). The neurodevelopmental basis of schizophrenia. Austin, TX: RG Landes Company, Chapman & Hall; 1996.
3. Rotrosen J, Wolkin A. Phospholipid and prostaglandin hypotheses of schizophrenia. In: Meltzer HY (ed). Psychopharmacology: the third generation of progress. New York: Raven Press; 1987. p. 759-764.
4. Horrobin DF, Glen AIM, Vaddadi KS. The membrane hypothesis of schizophrenia. Schizophr Res 1994;13:195-207.
5. Horrobin DF. Schizophrenia as a membrane lipid disorder, which is expressed throughout the body. Prostagland Leukotr Essent Fatty Acids 1996;55:3-7.
6. Horrobin DF. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr Res 1998;30:193-208.
7. Suzuki K. Chemistry and metabolism of brain lipids. In: Seigel DJ, Albers RW, Agranoff BW, et al (eds). Basic neurochemistry. 3rd ed. Boston: Little, Brown; 1981. p. 355-70.
8. Horrocks LA, Kanfer JN, Porcellati G (eds). Phospholipids in the nervous system. Vol 2. New York: Raven Press; 1982.
9. Mahadik SP, Mukherjee S. Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophr Res 1996;19:1-17.
10. Mahadik SP, Sitasawad S, Mulchandani M. Membrane peroxidation and the neuropathology of schizophrenia. In: Peet M, Glen I, Horrobin DF (eds). Phospholipid spectrum disorders in psychiatry. Lancashire: Marius Press; 1999. p. 99-111.
11. Agranoff B. Lipids. In: Siegel GJ, Albers RW, Agranoff BW, Katzman R (eds). Basic: neurochemistry. 4th ed. Boston: Little, Brown; 1989. p. 91-107.
12. 2 and arachidonic acid release in signal transduction. Biochem Soc Trans 1990;18:503-7.
13. Piomelli D, Pilon C, Giros B, et al. Dopamine activation of the arachidonic acid cascade as a basis for D1/D2 receptor synergism. Nature 1991;353:164-7.
14. Farooqui AA, Hirashima Y, Horrocks LA. Brain PLAs and their role in signal transduction. In: Toffano G, Murphy MG, Bazan N, editors. Neurobiology of essential fatty acids. New York: Plenum Press; 1992. p. 11-25.
15. Peet M, Glen I, Horrobin D (eds). Phospholipid spectrum disorders in psychiatry. Lancashire: Marius Press; 1999.
16. Mahadik SP, Evans D. Essential fatty acids in the treatment of schizophrenia. Drugs Today 1997;33:5-17.
17. Mahadik SP, Shendarkar NS, Scheffer R, et al. Utilization of precursor essential fatty acids in culture by skin fibroblasts from schizophrenic patients and normal controls. Prostagland Leukotr Essent Fatty Acids 1996;55:65-70.
18. Horrobin DF, Manku MS, Hillman H, et al. Fatty acid levels in the brains of schizophrenics and normal controls. Biol Psychiatry 1991;30:795-805.
19. Yao JK, Leonard S, Reddy RD. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophr Res 2000;42:7-17.
20. Keshavan MS, Mallinger AG, Pettegrew JW, et al. Erythrocyte membrane phospholipids in psychotic patients. Psychiatry Res 1993;49:89-95.
21. Mahadik SP, Mukherjee S, Correnti EE, et al. Plasma membrane phospholipid and cholesterol distribution of skin fibroblasts from drug-naive patients at the onset of psychosis. Schizophr Res 1994;13:239-47.
22. Yao JK, van Kammen DP, Welker JA. Red blood cell membrane dynamics: II. fatty acid composition. Schizophr Res 1994;13:217-26.
23. Glen AIM, Glen EMT, Horrobin DF, et al. A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases. Schizophr Res 1994;12:53-61.
24. Mahadik SP, Mukherjee S, Correnti EE, et al. Plasma membrane phospholipid fatty acid composition of cultured skin fibroblasts from schizophrenic patients: comparison with bipolar and normal subjects. Psychiatry Res 1996;63:133-42.
25. Assies J, Lieverse R, Vreken P, et al. Significantly reduced docosahexaenoic and docosapentaenoic acid concentrations in erythrocyte membranes from schizophrenic patients compared with a carefully matched control group. Biol Psychiatry 2001;49:510-22.
26. Khan MM, Evans DR, Gunna V, et al. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr Res 2002;58:1-10.
27. Christinsen O, Christinsen E. Fat consumption and schizophrenia. Acta Psychiat. Scand 1988;78:587-91.
28. Peet M, Laugharne J, Rangarajan N, et al. Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients. J Psychiatr Res 1995;29:227-32.
29. Mahadik SP, Mulchandani M, Hegde MV, et al. Cultural and socio-economic differences in dietary intake of essential fatty acids and antioxidants: effects on the course and outcome of schizophrenia. In: Peet M, Glen I, Horrobin D (eds). Phospholipid spectrum disorders in psychiatry. Lancashire: Marius Press; 1999. p. 167-79.
30. Arvindakshan M. Essential polyunsaturated fatty acid metabolism in schizophrenia outcome. PhD Thesis, Pune University, Pune, India, 2002.
31. Thompson GA (ed). The regulation of membrane lipid metabolism. 2nd ed. Boca Raton, FL: CRC Raven Press; 1992.
32. Burr GO, Burr MM. On the nature and the role of the fatty acids essential in nutrition. J Biol Chem 1930;85:587-621.
33. Carlson SE, Carver JD, House SC. High fat diets varying ratios of polyunsaturated to saturated fatty acids and linolenic acid, a comparison of rat neural and red cell membrane phospholipids. J Nutr 1986;116:718-25.
34. Neuringer M, Conner WE, Lin DS, et al. Biochemical and functional effects of prenatal and post-natal ω-3 fatty acid deficiency on retina and brain in rhesus monkeys. Proc Natl Acad Sci U S A 1986;83:4021-5.
35. Anderson GJ, Connor WE, Corliss JD. Docosahexaenoic acid is the preferred dietary n-3 fatty acid for the development of the brain and retina. Pediatr Res 1990;27:89-97.
36. Bourre JM, Bonneil M, Chaudiere J, et al. Structural and functional importance of dietary polyunsaturated fatty acids in the nervous system. In: Toffano G, Murphy MG, Bazan NG (eds). Neurobiology of essential fatty acids. New York: Plenum Press; 1992. p. 211-29.
37. Simopoulos AP. Omega-3 fatty acids in health and disease, and growth and development. Am J Clin Nutr 1991;54:438-63.
38. Wainwright PE. Do essential fatty acids play a role in brain and behavioral development? Neurosci Biobehav Res 1992;16:193-205.
39. 31P NMRS. Arch Gen Psychiatry 1991;48:563-8.
40. 31P magnetic resonance chemical shift imaging. Acta Psychiatr Scand 1992;86:455-62.
41. 31P MRS and MR1 studies. Schizophr Res 1993;10:241-6.
42. 31P-MR spectroscopy study. Schizophr Res 1994;13:209-15.
43. Fukuzako H, Fukuzako T, Takeuchi K, et al. Phosphorus magnetic resonance spectroscopy in schizophrenia: correlation between membrane PL metabolism in the temporal lobe and positive symptoms. Progr Neuropsychopharmacol Biol Psychiatry 1996;20:629-40.
44. Fukuzako H, Fukuzako T, Kodama S, et al. Haloperidol improves membrane phospholipid abnormalities in temporal lobes of schizophrenic patients. Neuropsychopharmacology 1999;21:542-9.
45. Jensen JE, Al-Salmaan YM, Williamson PC, et al. Region-specific changes in phospholipids metabolism in chronic, medicated schizophrenia. Br J Psychiatry 2002;180:39-44.
46. Katila H, Appleberg B, Rimon R. No differences in phospholipase-A2 activity between acute psychiatric patients and controls. Schizophr Res 1997;26:103-5.
47. Choudhari KV, Brandstaetter B, Semwal P, et al. Association studies of cytosolic phospholipase A2 polymorphisms and schizophrenia among two independent family-based samples. Psychiatric Gen 2001;1:207-12.
48. Scheffer RE, Bradley J, Mahadik SP. Elevated lipid peroxidation and phospholipase A2: possible mechanism of the lower cell membrane essential polyunsaturated fatty acids in schizophrenia. Biol Psychiatry 1999;43:101.
49. Reddy R, Yao J. Free radical pathology in schizophrenia: a review. Prostagland Leukotr Essent Fatty Acids 1996;55:33-43.
50. Mahadik SP, Mukherjee S, Scheffer R, et al. Elevated plasma lipid peroxides at the onset of nonaffective psychosis. Biol Psychiatry 1998;41:674-9.
51. Peet M, Laugharne J, Rangarajan N, et al. Tardive dyskinesia, lipid peroxidation, and sustained amelioration with vitamin E treatment. Int Clin Psychopharmacol 1993;8:151-3.
52. Arvindakshan M, Ghate M, Ranjekar PK, et al. Supplementation with a combination of ω-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophr Res 2002 (in press).
53. Roy D, Pathak DN, Singh R. Effects of chlorpromazine on the activities of antioxidant enzymes and lipid peroxidation in the various regions of aging rat brain. J Neurochem 1984;42:628-33.
54. Shivkumar BR, Ravindranath B. Oxidative stress and thiol modification induced by chronic administration of haloperidol. J Pharmacol Exp Ther 1993;265:1137-41.
55. Jedding I, Evans PJ, Akanmu D, et al. Characterization of the potential antioxidant and pro-oxidant actions of some neuroleptic drugs. Biochem Pharmacol 1995;49:359-65.
56. Subramanyam B, Rollema H, Wolf T, et al. Identification of a potentially neurotoxic pyridinium metabolite of haloperidol in rat. Biochem Biophys Res Commun 1990;166:238-44.
57. [571 Horrobin DF. The effects of antipsychotic drugs on membrane phospholipids - a possible novel mechanism of action of clozapine. In: Peet M, Glen I, Horrobin D (eds). Phospholipid spectrum disorders in psychiatry. Lancashire: Marius Press; 1999. p. 113-7.
58. Peet M, Horrobin DF. A dose-ranging exploratory study of the effects of ethyl-EPA in patients with persistent schizophrenic symptoms. J Psychiatr Res 2002;36:7-18.
59. Parikh V, Khan MM, White JR, et al. Atypical antipsychotics such as risperidone and clozapine do not induce the oxidative stress and the lipid peroxidation similar to haloperidol in rats. Biol Psychiatry 2002;51:184S-5S.
60. Thomas EA, Danielson PE, Nelson PA, et al. Clozapine increases apolipoprotein D expression in rodent brain: towards a mechanism for neuroleptic pharmacotherapy. J Neurochem 2001;76:789-96.
61. Khan MM, Parikh V, Mahadik SP. Effects of chronic exposure of antipsychotics on apolipoprotein D in rat brain. Biol Psychiatry 2002;51:168S.
62. Thomas EA, Dean B, Pavey G, et al. Increased CNS levels of apolipoprotein D in schizophrenic and bipolar subjects: implications for the pathophysiology of psychiatric disorder. Proc Natl Acad Sci U S A 2001;98:4066-71.
63. Mahadik SP, Khan MM, Evans DR, et al. Elevated plasma levels of apolipoprotein D in schizophrenia and implications for its treatment outcome. Schizophr Res 2002;58:55-62.
64. Kaiya H, Nishida A, Imai A, et al. Accumulation of diacylglycerol in platelet phosphoinositides turnover in schizophrenia: a biological marker of good prognosis? Biol Psychiatry 1989;26:669-76.
65. Essali MA, Das R, de Belleroche J, et al. The platelet polyphosphoinositide system in schizophrenia: the effects of neuroleptic treatment. Biol Psychiatry 1990;28:478-87.
66. Yao JK, Yasaei P, van Kammen DP. Increased turnover of platelet phosphatidylinositol in schizophrenia. Prostagland Leukotr Essential Fatty Acids 1992;46:39-46.
67. Hudson CJ, Young TL, Li PP, et al. CNS signal transduction and pathophysiology and pharmacotherapy of affective disorder and schizophrenia. Synapse 1993;13:278-93.
68. Braff D. Information processing and attention dysfunctions in schizophrenia. Schizophr Bull 1993;19:233-60.
69. Khan A, Khan SR, Leventhal RM, et al. Symptom reduction and suicide risk among treated with placebo in antipsychotic clinical trials: an analysis of the Food and Drug Administration database. Am J Psychiatry 2001;158:1449-54.
70. Hegarty JD, Baldessarini RJ, Tohen M, et al. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry 1994;151:1409-16.
71. Fenton WS, Hibbelin J, Knable M. Essential fatty acids, lipid membrane abnormalities, and the diagnosis of schizophrenia. Biol Psychiatry 2000;47:8-12.
72. Fenton WS, Dickerson F, Boronow J, et al. A placebo controlled trial of omega-3 fatty acids (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry 2001;158:2071-4.
73. Tsay HJ, Wang P, Wang SL, et al. Age-associated changes of superoxide dismutase and catalase activities in the rat brain. J Biomed Sci 2000;7:466-74.
74. Vaddadi KS, Courtney P, Gilleard CJ, et al. A double-blind trial of essential fatty acids supplementation in patients with tardive dyskinesia. Psychiatry Res 1989;27:313-23.
75. Peet M, Brind J, Ramchand CN, et al. Two double blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr Res 2001;49:243-51.
76. Rafalowska U, Liu G-J, Floyd RA. Peroxidation induced changes in synaptosomal transport of dopamine and gamma-aminobutyric acid. Free Rad Biol Med 1989;6:485-92.
77. Schwartz RD, Skolnick P, Paul SM. Regulation of gamma-aminobutyric acid/barbiturate receptor gated chloride ion flux in brain vesicles by phospholipase A2: possible role of oxygen radicals. J Neurochem 1988;50:565-71.
78. Mahadik SP, Evans D, Lal H. Oxidative stress and role of antioxidant and ω-3 essential fatty acid supplementation in schizophrenia. Progr Neuropsychopharmacol Biol Psychiatry 2001;25:263-93.
79. Adler LA, Peselow E, Rotrosen J, et al. Vitamin E treatment of tardive dyskinesia. Am J Psychiatry 1993;150:1405-7.
80. Adler LA, Rotrosen J, Edson R, et al. Vitamin E treatment for tardive dyskinesia. Arch J Psychiatry 1999;56:836-41.
81. Mahadik SP, Gowda S. Antioxidants in the treatment of schizophrenia. Drugs Today 1996;32:1-13.
82. Mahadik SP, Evans DR, Terry A, et al. Neuroprotective action of atypical antipsychotics in schizophrenia: improved cognitive performance and underlying mechanism of action. Schizophr Res 2001;49:94.